SYSTM Wealth Solutions LLC Sells 5,663 Shares of TransMedics Group, Inc. (NASDAQ:TMDX)

SYSTM Wealth Solutions LLC lowered its position in shares of TransMedics Group, Inc. (NASDAQ:TMDX) by 35.7% during the second quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 10,188 shares of the company’s stock after selling 5,663 shares during the period. SYSTM Wealth Solutions LLC’s holdings in TransMedics Group were worth $1,535,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Fidelis Capital Partners LLC bought a new stake in TransMedics Group during the 1st quarter worth $35,000. International Assets Investment Management LLC bought a new stake in TransMedics Group during the 2nd quarter worth $47,000. J.Safra Asset Management Corp lifted its holdings in TransMedics Group by 649.2% during the 2nd quarter. J.Safra Asset Management Corp now owns 442 shares of the company’s stock worth $67,000 after buying an additional 383 shares during the period. Signaturefd LLC lifted its holdings in TransMedics Group by 26.6% during the 2nd quarter. Signaturefd LLC now owns 443 shares of the company’s stock worth $67,000 after buying an additional 93 shares during the period. Finally, Entropy Technologies LP acquired a new position in TransMedics Group during the 1st quarter worth about $201,000. Institutional investors own 99.67% of the company’s stock.

Insiders Place Their Bets

In other TransMedics Group news, insider Tamer I. Khayal sold 2,958 shares of the firm’s stock in a transaction dated Thursday, August 1st. The shares were sold at an average price of $156.77, for a total value of $463,725.66. Following the completion of the sale, the insider now directly owns 20,843 shares in the company, valued at $3,267,557.11. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In other news, CEO Waleed H. Hassanein sold 8,625 shares of TransMedics Group stock in a transaction that occurred on Monday, July 15th. The shares were sold at an average price of $145.17, for a total transaction of $1,252,091.25. Following the completion of the transaction, the chief executive officer now directly owns 61,643 shares in the company, valued at $8,948,714.31. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Tamer I. Khayal sold 2,958 shares of TransMedics Group stock in a transaction that occurred on Thursday, August 1st. The shares were sold at an average price of $156.77, for a total transaction of $463,725.66. Following the transaction, the insider now owns 20,843 shares of the company’s stock, valued at $3,267,557.11. The disclosure for this sale can be found here. Insiders sold 61,247 shares of company stock worth $9,650,880 over the last three months. Company insiders own 7.00% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have commented on TMDX shares. Oppenheimer lifted their target price on TransMedics Group from $125.00 to $200.00 and gave the stock an “outperform” rating in a report on Thursday, August 1st. Canaccord Genuity Group upped their price target on TransMedics Group from $117.00 to $169.00 and gave the stock a “buy” rating in a research note on Thursday, August 1st. Needham & Company LLC began coverage on TransMedics Group in a research note on Wednesday, August 21st. They set a “buy” rating and a $208.00 price target on the stock. Piper Sandler boosted their price objective on TransMedics Group from $170.00 to $180.00 and gave the stock an “overweight” rating in a report on Thursday, August 1st. Finally, Cantor Fitzgerald started coverage on TransMedics Group in a report on Thursday, June 6th. They issued an “overweight” rating and a $161.00 target price for the company. One equities research analyst has rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $171.44.

TransMedics Group Stock Up 3.2 %

NASDAQ TMDX opened at $156.08 on Wednesday. The company has a debt-to-equity ratio of 2.67, a current ratio of 9.37 and a quick ratio of 8.48. The stock has a market capitalization of $5.21 billion, a PE ratio of -459.06 and a beta of 1.99. TransMedics Group, Inc. has a 1 year low of $36.42 and a 1 year high of $177.37. The business’s 50-day moving average is $154.40 and its 200 day moving average is $127.98.

TransMedics Group (NASDAQ:TMDX) last posted its earnings results on Wednesday, July 31st. The company reported $0.35 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.21 by $0.14. The company had revenue of $114.30 million for the quarter, compared to analysts’ expectations of $98.84 million. TransMedics Group had a return on equity of 15.98% and a net margin of 0.84%. TransMedics Group’s quarterly revenue was up 117.7% on a year-over-year basis. During the same period last year, the firm earned ($0.03) earnings per share. Sell-side analysts forecast that TransMedics Group, Inc. will post 1.23 earnings per share for the current year.

TransMedics Group Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.